TNC
TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.
Overview
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Gemcitabine. IntOGen calls it a driver in 7 cohorts (5 activating, 2 loss-of-function), covering Adrenocortical Carcinoma, Acute Myeloid Leukaemia, Bladder/Urinary Tract, Lung Squamous Cell Carcinoma, Malignant Lymphoma, Neuroblastoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.
- 1 · What it is
TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.
- 2 · What goes wrong in cancer
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration.
- 3 · How drugs use it
No product in this corpus aims at TNC yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:5318 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P24821 (protein name, function text, keywords and locations (REST API)); CIViC gene TNC (2 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Cancer (GraphQL API, CC0)); IntOGen TNC (driver in 7 cohorts (Act 5, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumours, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 9q33.1 (HGNC).
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
- Adrenocortical carcinoma: IntOGen driver in 1 cohort (ACC)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLADDER)
- Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Acute myeloid leukaemia: IntOGen driver in 1 cohort (AML)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TNC" OR ABSTRACT:"TNC" OR TITLE:"tenascin C" OR ABSTRACT:"tenascin C" OR TITLE:"Tenascin" OR ABSTRACT:"Tenascin" OR TITLE:"MGC167029" OR ABSTRACT:"MGC167029" OR TITLE:"DFNA56" OR ABSTRACT:"DFNA56") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNC, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetETV4
Shares Neuroblastoma (paediatric), CIViC, IntOGen, Pancreatic ductal adenocarcinoma.
- TargetFBLN2
Shares Neuroblastoma (paediatric), Bladder & urothelial cancer, IntOGen, Pancreatic ductal adenocarcinoma.
- TargetBCORL1
Shares Neuroblastoma (paediatric), Acute myeloid leukaemia, IntOGen, Pancreatic ductal adenocarcinoma.
- TargetBCOR
Shares Adrenocortical carcinoma, Non-Hodgkin lymphoma (all types), CIViC, IntOGen.
- TargetATRX
Shares Adrenocortical carcinoma, CIViC, IntOGen, Ovarian cancer.
- TargetZNRF3
Shares Adrenocortical carcinoma, IntOGen.
- TargetPRKAR1A
Shares Adrenocortical carcinoma, CIViC, IntOGen.
- TargetDAXX
Shares Adrenocortical carcinoma, IntOGen, Pancreatic ductal adenocarcinoma.